CEL-SCI reports on adjuvant properties of CEL-1000 peptide to enhance vaccines

Zimmerman: "CEL-1000 does not appear to induce self- directed or cross-reactive antibodies, can be well characterized and is inexpensive to manufacture."

06-Jun-2003

Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular immunology at CEL-SCI Corporation today reported at the conference Modern vaccines, adjuvants and Delivery Systems in Dublin, Ireland on the potential use of the Company's CEL-1000 peptide as an adjuvant for vaccines. Adjuvants are immuno-potentiators designed to improve the effectiveness of vaccines.

Dr. Zimmerman presented data from several animal experiments conducted in collaboration with the laboratories of Dr. Kenneth S. Rosenthal of Northeastern Ohio Universities College of Medicine for Herpes Simplex, Dr. Yupin Charoenvit of the National Naval Medical Research Center (NMRC) for malaria and Dr. Michael Whelan of Onyvax, Ltd. of London for cancer. In addition Dr. Zimmerman presented data derived from his own laboratory at CEL- SCI for HIV. All four disease-testing systems demonstrated that CEL-1000 by itself or in a peptide conjugate produced an increased response and protection from death and significantly improved the cellular immune responses, depending on the testing involved and what was being measured.

Dr. Zimmerman said, "We believe that CEL-1000 would make a good adjuvant for several additional reasons. CEL-1000 does not appear to induce self- directed or cross-reactive antibodies, can be well characterized and is inexpensive to manufacture."

CEL-SCI recently received a Phase I SBIR grant of $162,000 from National Institutes of Health for development of a therapeutic treatment using CEL-1000 for Herpes Simplex virus.

Dr. Rosenthal is already working with the CEL-1000 peptide and also recently received a $1.1 million grant for collaborative studies with CEL-SCI for the development of CEL-1000 as a possible treatment for viral encephalitis. Viral encephalitis is a potentially lethal inflammation of the brain.

CEL-1000 is a modified version of a human immune-based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response.

Other news from the department science

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous